Stay updated with breaking news from Kevan Herold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The work of Jeffrey Bluestone, who will be inducted into the Rutgers University Hall of Distinguished Alumni, has led to new treatments for cancer and autoimmune diseases.
Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, discussed recently published results from the PROTECT trial of teplizumab in patients newly diagnosed with type 1 diabetes (T1D).
In this episode, hosts discuss data from the PROTECT trial, which examined the effects of teplizumab on beta-cell function in patients with newly diagnosed type 1 diabetes.
A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md.,...
The preservation of insulin-producing beta cells is just one of the benefits of teplizumab, also known as Tzield, a phase 3 trial shows.